About EnClear Therapies
EnClear Therapies is a company based in Cambridge (United States) founded in 2018.. EnClear Therapies has raised $12.72 million across 4 funding rounds from investors including Leland Stanford Junior University, GF Securities and HHS. EnClear Therapies offers products and services including EnTrega CSF Platform. EnClear Therapies operates in a competitive market with competitors including Newronika, NovaVision, MindAffect, Actipulse Neuroscience and AccuMedical, among others.
- Headquarter Cambridge, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Clear Therapies Ltd
-
Annual Revenue
$29.03 K (USD)14as on Oct 31, 2022
-
Net Profit
$21.72 K (USD)5as on Oct 31, 2022
-
EBITDA
-
Total Equity Funding
$12.72 M (USD)
in 4 rounds
-
Latest Funding Round
$3.86 M (USD), Grant
Jul 01, 2024
-
Investors
Leland Stanford Junior University
& 11 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of EnClear Therapies
EnClear Therapies offers a comprehensive portfolio of products and services, including EnTrega CSF Platform. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Platform for accurate dosing of CNS therapeutics to minimize side effects.
Unlock access to complete
Unlock access to complete
Funding Insights of EnClear Therapies
EnClear Therapies has successfully raised a total of $12.72M across 4 strategic funding rounds. The most recent funding activity was a Grant round of $3.86 million completed in July 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Grant — $3.9M
-
First Round
First Round
(14 Mar 2019)
- Investors Count 12
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2024 | Amount | Grant - EnClear Therapies | Valuation |
investors |
|
| Feb, 2024 | Amount | Series A - EnClear Therapies | Valuation |
investors |
|
| Feb, 2020 | Amount | Series A - EnClear Therapies | Valuation | 20/20 HealthCare Partners |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in EnClear Therapies
EnClear Therapies has secured backing from 12 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Leland Stanford Junior University, GF Securities and HHS. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage investments are made in healthcare technology and life sciences.
|
Founded Year | Domain | Location | |
|
Thiel Capital is involved in investment and financial activities.
|
Founded Year | Domain | Location | |
|
Venture capital investments are facilitated by Amgen-backed entity.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by EnClear Therapies
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - EnClear Therapies
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Enclear Therapies Comparisons
Competitors of EnClear Therapies
EnClear Therapies operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Newronika, NovaVision, MindAffect, Actipulse Neuroscience and AccuMedical, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Medical devices for neurodegenerative diseases are developed.
|
|
| domain | founded_year | HQ Location |
Non-invasive devices are developed for vision restoration in stroke survivors.
|
|
| domain | founded_year | HQ Location |
Brain-computer interface headsets are developed for patient communication.
|
|
| domain | founded_year | HQ Location |
Non-invasive brain stimulation technology is developed for neurodegenerative disorders.
|
|
| domain | founded_year | HQ Location |
Neurovascular interventional devices for neurological disorders are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Enclear Therapies
Frequently Asked Questions about EnClear Therapies
When was EnClear Therapies founded?
EnClear Therapies was founded in 2018 and raised its 1st funding round 1 year after it was founded.
Where is EnClear Therapies located?
EnClear Therapies is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Is EnClear Therapies a funded company?
EnClear Therapies is a funded company, having raised a total of $12.72M across 4 funding rounds to date. The company's 1st funding round was a Series A of $10M, raised on Mar 14, 2019.
What is the annual revenue of EnClear Therapies?
Annual revenue of EnClear Therapies is $29.03K as on Oct 31, 2022.
What does EnClear Therapies do?
EnClear Therapies was founded in 2018 and is headquartered in Cambridge, United States. Device-based therapies are developed by the company to address neurodegenerative disorders, including Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP). The technology is designed to recirculate cerebrospinal fluids and eliminate toxic proteins from brain and spinal fluids, supporting treatment efforts in the medical device sector.
Who are the top competitors of EnClear Therapies?
EnClear Therapies's top competitors include Newronika, NovaVision and Actipulse Neuroscience.
What products or services does EnClear Therapies offer?
EnClear Therapies offers EnTrega CSF Platform.
Who are EnClear Therapies's investors?
EnClear Therapies has 12 investors. Key investors include Leland Stanford Junior University, GF Securities, HHS, Bioverge, and 20/20 HealthCare Partners.